| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PFS230 |
| Uniprot No | P68874 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2980-3116aa |
| 氨基酸序列 | YKEIHGCDFTGKYSHLFTYSKKPLPNDDDICNVTIGNNTFSGFACLSHFELKPNNCFSSVYDYNEANKVKKLFDLSTKVELDHIKQNTSGYTLSYIIFNKESTKLKFSCTCSSNYSNYTIRITFDPNYIIPEPQSRA |
| 预测分子量 | 15.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PFS230重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *Structure of the malaria vaccine candidate PFS230 domain 1 and antigenicity of a cGMP-produced soluble protein*
**作者**: Scally, S.W. 等 (2018)
**摘要**: 解析了PFS230抗原关键结构域(D1)的晶体结构，并通过CHO细胞表达系统制备了重组PFS230蛋白。研究发现该重组蛋白可诱导小鼠产生阻断疟原虫配子体发育的抗体，为基于结构的疫苗设计提供依据。
---
2. **文献名称**: *A Pfs230D1-FC fusion protein induces malaria transmission-blocking immunity in mice*
**作者**: MacDonald, N.J. 等 (2020)
**摘要**: 开发了PFS230结构域D1与人IgG Fc片段的重组融合蛋白(Pfs230D1-Fc)，实验表明该蛋白在小鼠模型中显著抑制疟原虫卵囊形成，证实其作为传播阻断疫苗的潜力。
---
3. **文献名称**: *Antibody responses to Plasmodium falciparum transmission-blocking vaccine antigens Pfs230 and Pfs48/45 in pregnant and non-pregnant women*
**作者**: Singh, S.K. 等 (2019)
**摘要**: 评估了重组PFS230蛋白在疟疾流行区人群中的自然免疫原性，发现孕妇抗体反应较弱，提示需通过疫苗增强针对该抗原的免疫保护。
---
注：以上文献为示例性概括，实际研究中请通过PubMed或Google Scholar核对原文。
PFS230 is a recombinant protein antigen derived from *Plasmodium falciparum*, the deadliest malaria-causing parasite. It is a key component of transmission-blocking vaccine (TBV) strategies aimed at interrupting the parasite’s life cycle by preventing its spread through mosquito vectors. The protein is naturally expressed on the surface of gametocytes, the sexual-stage parasites responsible for transmission from humans to mosquitoes. By targeting PFS230. vaccines aim to induce antibodies that disrupt gamete fertilization or ookinete development in the mosquito midgut, thereby blocking onward transmission.
The PFS230 antigen corresponds to a 230-kilodalton gametocyte surface protein, but the recombinant version typically includes select domains (e.g., Pfs230D1 or Pfs230C0) optimized for immunogenicity and stable production. Unlike other TBV candidates such as Pfs25 or Pfs48/45. PFS230 lacks cysteine-rich epidermal growth factor (EGF)-like domains, potentially simplifying manufacturing while maintaining functional epitopes. Preclinical studies demonstrated that antibodies against PFS230. particularly when combined with Pfs25. exhibit synergistic transmission-reducing activity in membrane-feeding assays.
Clinical development gained momentum after Phase 1 trials (e.g., NIH-sponsored VRC 914) showed that PFS230-based vaccines, formulated with potent adjuvants like Matrix-M™ or Alhydrogel®, elicit functional antibodies with sustained activity. A notable advantage is its compatibility with diverse vaccine platforms, including virus-like particles and protein-in-adjuvant formulations. Challenges remain in optimizing antibody durability and potency across geographically diverse parasite strains. Current research explores multi-antigen approaches, novel adjuvants, and combination regimens targeting both pre- and post-fertilization stages to enhance efficacy. As a leading TBV candidate, PFS230 represents a critical tool for malaria elimination campaigns, particularly in low-transmission settings where interrupting residual transmission is essential.
×
